Physician profile
Whitney Genrich
NPI 1154735348
$1,732.91
in general payments reported to CMS, 2019-2025
17 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $157 · 2021: $211 · 2022: $239 · 2023: $215 · 2024: $380 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $952.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $677.11 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens |
| Bausch & Lomb Americas INC. | $219.61 | 2023-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $206.29 | 2019-2024 | Total30 |
| Sun Pharmaceutical Industries INC. | $94.35 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $81.93 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $78.48 | 2020-2022 | |
| Biotissue Holdings INC. | $50.48 | 2024-2025 | |
| Oyster Point Pharma, INC. | $50.34 | 2022-2024 | Ryzumvi, Tyrvaya |
| Apellis Pharmaceuticals, INC. | $46.36 | 2025 | Syfovre |
| Harrow Eye, LLC | $45.45 | 2025 | Vevye |
| Dompe US, INC. | $43.76 | 2024-2025 | Oxervate |
| Shire North American Group INC | $27.35 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $27.29 | 2025 | Xdemvy |
| Abbvie INC. | $26.63 | 2024 | |
| Mallinckrodt Hospital Products INC. | $24.01 | 2024 | Acthar |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $19.78 | 2021 | |
| Allergan, INC. | $13.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Genrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.